Clinigen Group plc Issue of Equity (7358A)
June 03 2019 - 3:00AM
UK Regulatory
TIDMCLIN
RNS Number : 7358A
Clinigen Group plc
03 June 2019
3 June 2019
Issue of Equity
Clinigen Group plc (AIM: CLIN, the "Group") announces that it
has made an application for the admission to trading on AIM of
46,075 ordinary shares of 0.1 pence each in the Group (the "New
Ordinary Shares"). These New Ordinary Shares have been issued to
satisfy share options vesting under the 2016 Clinigen Group
Sharesave Plan and corresponding 2017 US Purchase Plan and rank
pari passu with the existing shares of the Group. Admission to
trading on AIM of the New Ordinary Shares is anticipated to occur
on 5 June 2019.
At admission the issued share capital of the Group will consist
of 132,479,167 ordinary shares, with no shares held in treasury.
The total number of voting rights in the Group will therefore be
132,479,167. This figure may be used by shareholders as the
denominator to determine if they are required to notify their
interests in, or a change to their interests in, the Group under
the Disclosure Guidance and Transparency Rules.
-Ends-
Contact details
Clinigen Group plc Tel: +44 (0) 1283 495010
Shaun Chilton, Group Chief Executive Officer
Nick Keher, Group Chief Financial Officer
Matt Parrish, Head of Investor Relations
Numis Securities Limited - Nominated Adviser Tel: +44 (0) 20 7260
& Joint Broker 1000
James Black / Freddie Barnfield / Freddie
Naylor-Leyland
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653
4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457
2020
Melanie Toyne-Sewell / Alex Shaw / Deborah
Bell Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. The Group has sites in North America,
Europe, Africa and Asia Pacific. In October 2018, the Group
acquired CSM, a specialist provider of packaging, labelling,
warehousing and distribution services, with sites in the US and
Europe, and iQone, a specialist pharmaceutical company in
Switzerland.
For more information, please visit www.clinigengroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOESDWSWFFUSELI
(END) Dow Jones Newswires
June 03, 2019 04:00 ET (08:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2023 to Apr 2024